S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
No currency manipulator labels from US, China on watch
The Top 3 Stocks to Buy in December
Marvell Technology (NASDAQ:MRVL) a Buy After its Marvelous Q3
Stocks churn higher on Wall Street, capping a volatile week
US jobless rate sinks to 4.2% as many more people find jobs
Wall Street's wild swings continue as stocks rise, then fall
Stocks sink after Wall Street takes another sharp U-turn
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
No currency manipulator labels from US, China on watch
The Top 3 Stocks to Buy in December
Marvell Technology (NASDAQ:MRVL) a Buy After its Marvelous Q3
Stocks churn higher on Wall Street, capping a volatile week
US jobless rate sinks to 4.2% as many more people find jobs
Wall Street's wild swings continue as stocks rise, then fall
Stocks sink after Wall Street takes another sharp U-turn
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
No currency manipulator labels from US, China on watch
The Top 3 Stocks to Buy in December
Marvell Technology (NASDAQ:MRVL) a Buy After its Marvelous Q3
Stocks churn higher on Wall Street, capping a volatile week
US jobless rate sinks to 4.2% as many more people find jobs
Wall Street's wild swings continue as stocks rise, then fall
Stocks sink after Wall Street takes another sharp U-turn
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
No currency manipulator labels from US, China on watch
The Top 3 Stocks to Buy in December
Marvell Technology (NASDAQ:MRVL) a Buy After its Marvelous Q3
Stocks churn higher on Wall Street, capping a volatile week
US jobless rate sinks to 4.2% as many more people find jobs
Wall Street's wild swings continue as stocks rise, then fall
Stocks sink after Wall Street takes another sharp U-turn
CVE:HLS

HLS Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
49,300 shs
Average Volume
97,793 shs
Market Capitalization
C$384.86 million
P/E Ratio
N/A
Dividend Yield
1.46%
Beta
N/A

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


HLS Therapeutics logo

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.

Headlines

HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference
December 1, 2021 |  finance.yahoo.com
HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
September 8, 2021 |  finance.yahoo.com
BRIEF-HLS Therapeutics Announces Promotional Agreement With Pfizer For Vascepa
August 16, 2021 |  msn.com
HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada
August 16, 2021 |  finance.yahoo.com
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of CA$0.05
August 10, 2021 |  finance.yahoo.com
HLS Therapeutics Announces Second Quarter Fiscal 2021 Financial Results
August 5, 2021 |  finance.yahoo.com
Here's what Wall Street expects from HLS Therapeutics's earnings
August 3, 2021 |  markets.businessinsider.com
HLS Therapeutics to Participate in Virtual Non-...
June 9, 2021 |  benzinga.com
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 10, 2021
June 9, 2021 |  finance.yahoo.com
HLS Therapeutics Announces Participation in Upcoming Conferences
April 15, 2021 |  finance.yahoo.com
HLS Therapeutics is about to announce earnings — here's what Wall Street expects
March 18, 2021 |  markets.businessinsider.com
Form D Friday: Investors value semiconductors, clinical trial software
March 5, 2021 |  bizjournals.com
HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021
February 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:HLS
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.hlstherapeutics.com
Phone
647-495-9000
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
C$65.13 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
38.84
Book Value
C$6.11 per share
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
60.11
Current Ratio
0.84
Quick Ratio
0.75

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
27,295,300
Free Float
N/A
Market Cap
C$384.86 million
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












HLS Therapeutics (CVE:HLS) Frequently Asked Questions

Is HLS Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLS Therapeutics stock.
View analyst ratings for HLS Therapeutics or view top-rated stocks.

Is HLS Therapeutics a good dividend stock?

HLS Therapeutics pays an annual dividend of C$0.20 per share and currently has a dividend yield of 1.46%.

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)
  • Mr. Gilbert Godin, Pres & COO (Age 59)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)
  • Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50)

What other stocks do shareholders of HLS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), ProMetic Life Sciences (PLI), Ritter Pharmaceuticals (RTTR), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE) and Apellis Pharmaceuticals (APLS).

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS."

How much money does HLS Therapeutics make?

HLS Therapeutics has a market capitalization of C$0.00 and generates C$65.13 million in revenue each year.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.